Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply

Affiliations

¹ Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address: syylwu@live.cn.
² Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

Comment

Yi-Long Wu et al. Lancet Oncol. 2018 Mar.

. 2018 Mar;19(3):e127.

doi: 10.1016/S1470-2045(18)30133-5.

¹ Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address: syylwu@live.cn.
² Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

No abstract available

Comment on

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
Wu F, Liu X, Ma JA, Gao Y, Hu C. Wu F, et al. Lancet Oncol. 2018 Mar;19(3):e124. doi: 10.1016/S1470-2045(18)30073-1. Lancet Oncol. 2018. PMID: 29508749 No abstract available.
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
Ma JA, Jiang S, Hu C, Xie Y, Hou T. Ma JA, et al. Lancet Oncol. 2018 Mar;19(3):e125. doi: 10.1016/S1470-2045(18)30074-3. Lancet Oncol. 2018. PMID: 29508750 No abstract available.
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
Rosell R, Karachaliou N. Rosell R, et al. Lancet Oncol. 2018 Mar;19(3):e126. doi: 10.1016/S1470-2045(18)30071-8. Lancet Oncol. 2018. PMID: 29508751 No abstract available.